Shots:

• The EC has signed an agreement to supply Roche’s RoActemra and Merck’s Rebif in 27 EU member states willing to buy the therapies to combat the pandemic. The agreement follows requests from EU states in May to acquire the two drugs having the potential to target COVID-19
• In a discussion with EC- Roche has committed to meet the need for eligible patients with COVID-19 associated pneumonia in the EU & across the globe in an equitable and sustainable manner. On Jul 08- 2020- EC asked Merck to be prepared to supply Rebif in EU states
• Roche is evaluating RoActemra in 330 COVID -19 patients and also assessing it in combination with Gilead’s Remdesivir while Rebif was developed by Serono before Merck acquired the company

Click here to read full press release/ article 

Ref: Reuters | Image: Merck